Lenacapavir Sodium API CAS 2189684-44-2

Lenacapavir sodium API CAS 2189684-44-2 works by inhibiting the HIV-1 capsid protein, a protein shell that encapsulates the virus's genetic material and is involved in multiple stages of the HIV life cycle. Lenacapavir is the first product approved for inhibiting the HIV-1 capsid, providing a new treatment option for HIV-infected adults.

Lenacapavir exerts a triple antiviral effect by specifically binding to HIV-1 capsid protein monomers, including disrupting capsid assembly, inhibiting uncoating, and suppressing nuclear translocation, thereby interfering with viral replication in host cells.

Lenacapavir sodium API CAS 2189684-44-2 targets the HIV integrase, a crucial enzyme in viral replication. HIV requires integrase to insert its genome into the chromosome of human immune cells (CD4+ T cells) to complete replication and spread. Similar to traditional INSTI products, Lenacapavir inhibits the strand transfer activity of integrase, preventing the integration of viral DNA with host cell DNA and thus interrupting the viral replication cycle. However, its unique feature is the more stable binding mechanism of Lenacapavir to integrase, resulting in a longer half-life of the formed complex, allowing it to maintain effective concentrations in vivo for up to 6 months.